ArticleJournal of thoracic disease2026
Factors associated with upstaging in patients with resectable non-small cell lung cancer: a modern institutional sample.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- What affects adequate lymph node harvest in pulmonary resections?-assessment of compliance with a national quality standard.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is significant value in predicting and better assessing patients who are at risk of post-surgery upstaging in lung cancer. The objective of this study is to review patients who were upstaged following resection and evaluate their clinical and demographic data to elucidate which factors portend an increased risk of pathologic upstaging at our institution (the Thomas Jefferson University Hospital). Methods: A retrospective review of institutional data was performed between 2011 and 2023. Patients with stage I-II non-small cell lung cancer (NSCLC) were included. Patients were excluded if they received neoadjuvant systemic therapy, including chemotherapy and/or immunotherapy, and were excluded if they received pre-operative mediastinoscopy or endobronchial ultrasound (EBUS). Kaplan-Meier analysis was utilized with log-rank testing to examine 5-year overall survival and progression-free survival. A logistic regression model was built to evaluate whether certain clinical or demographic factors affect the odds of being upstaged. Results: A total of 371 patients met the inclusion criteria. Male sex, primary tumor standardized uptake value (SUV) >8, pre-operative biopsy, and having 10-13 lymph nodes explored were all associated with increased odds of being upstaged. Squamous cell histology was associated with lower odds of upstaging compared to adenocarcinoma. Patients who had their tumor detected via a screening computed tomography (CT) scan had a trend towards a decreased odds of upstaging compared to symptomatic and incidentally found tumors. Conclusions: Male gender, primary tumor SUV >8, having a preoperative biopsy, and having 10-13 lymph nodes explored were associated with increased odds of being upstaged. This analysis provides patients and clinicians with valuable data regarding upstaging early-stage lung cancers, which could be used to guide multidisciplinary teams in making more informed decisions regarding resection and the use of perioperative systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.